acute ischemic stroke
Conditions
Interventions
Test group:rTMS treatment
Control group:sham-rTMS treantment
Sponsors
The First Hospital of Jilin University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Age >=18 years, regardless of gender; (2) A clear clinical diagnosis of acute anterior circulation ischemic stroke; (3) Baseline (pre-randomization) NIHSS score of 6–16, with a single-limb item score >=2; (4) Pre-stroke modified Rankin Scale (mRS) score <=1; (5) Ability to complete randomization and initiate transcranial magnetic stimulation within 3 days of symptom onset; (6) Written informed consent provided by the participant or their legally authorized representative.
Exclusion criteria
Exclusion criteria: (1) Intracranial hemorrhagic conditions identified on neuroimaging, including hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, and subarachnoid hemorrhage; (2) Presence of severe cognitive impairment or psychiatric disorders; (3) Presence of severe systemic disease or a history of cranial/brain surgery; (4) A history of epilepsy, a family history of epilepsy, or the presence of factors predisposing to epileptic seizures; (5) Known pregnancy or breastfeeding; (6) Presence of metallic foreign bodies near the stimulation site, such as intracranial metal implants, cochlear implants, or implanted pulse generators (e.g., brain stimulators or cardiac pacemakers); (7) Patients with an expected survival of less than 3 months, or those unable to complete the study for other reasons; (8) Unwillingness to undergo follow-up or poor treatment adherence; (9) Patients being enrolled or having been enrolled in another clinical trial within the 3 months prior to this clinical trial; (10) Any other condition deemed unsuitable for enrollment by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients with an mRS score of 0-1 at 90 days; | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of patients with an mRS score of 0-2 at 90 days;The distribution of mRS scores at 90 days;The proportion of patients with early neurological improvement between the two groups (defined as a reduction of =4 in the NIHSS score from baseline, or an NIHSS score of 0–1 at the end of the 7-day rTMS/sham-rTMS treatment).;The proportion of patients with early neurological deterioration between the two groups (defined as an increase of =4 in the NIHSS score from baseline at the end of the 7-day rTMS/sham-rTMS treatment);The NIHSS scores between the two groups after 7 days of treatment;The final cerebral infarct volume between the two groups; | — |
Countries
China
Contacts
Public ContactYi Yang
The First Hospital of Jilin University
Outcome results
None listed